JP6987749B2 - Ｓｋチャネル阻害剤による学習障害および他の神経障害の治療 - Google Patents

Ｓｋチャネル阻害剤による学習障害および他の神経障害の治療 Download PDF

Info

Publication number
JP6987749B2
JP6987749B2 JP2018519450A JP2018519450A JP6987749B2 JP 6987749 B2 JP6987749 B2 JP 6987749B2 JP 2018519450 A JP2018519450 A JP 2018519450A JP 2018519450 A JP2018519450 A JP 2018519450A JP 6987749 B2 JP6987749 B2 JP 6987749B2
Authority
JP
Japan
Prior art keywords
tamapin
tamapine
pharmaceutical composition
subject
channel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018519450A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018534287A (ja
JP2018534287A5 (https=
Inventor
和枝 鳥居
正昭 鳥居
シャヒド、モハマド
宏樹 森園
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Childrens National Medical Center Inc
Original Assignee
Childrens National Medical Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens National Medical Center Inc filed Critical Childrens National Medical Center Inc
Publication of JP2018534287A publication Critical patent/JP2018534287A/ja
Publication of JP2018534287A5 publication Critical patent/JP2018534287A5/ja
Application granted granted Critical
Publication of JP6987749B2 publication Critical patent/JP6987749B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
JP2018519450A 2015-10-13 2016-10-13 Ｓｋチャネル阻害剤による学習障害および他の神経障害の治療 Active JP6987749B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562240561P 2015-10-13 2015-10-13
US62/240,561 2015-10-13
PCT/US2016/056835 WO2017066444A1 (en) 2015-10-13 2016-10-13 Treatment of learning disabilities and other neurological disorders with sk channel inhibitor(s)

Publications (3)

Publication Number Publication Date
JP2018534287A JP2018534287A (ja) 2018-11-22
JP2018534287A5 JP2018534287A5 (https=) 2019-12-19
JP6987749B2 true JP6987749B2 (ja) 2022-01-05

Family

ID=58518316

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018519450A Active JP6987749B2 (ja) 2015-10-13 2016-10-13 Ｓｋチャネル阻害剤による学習障害および他の神経障害の治療

Country Status (4)

Country Link
US (1) US10555989B2 (https=)
EP (1) EP3362081B1 (https=)
JP (1) JP6987749B2 (https=)
WO (1) WO2017066444A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113422142B (zh) * 2021-05-18 2022-06-24 金华职业技术学院 一种新能源汽车电池模组高效散热装置
GB202313820D0 (en) * 2023-09-11 2023-10-25 Imperial College Innovations Ltd Peptide

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2918282B1 (fr) * 2007-07-02 2009-10-02 Assistance Publique Hopitaux P Medicament pour le traitement de la maladie de parkinson
WO2010015037A1 (en) * 2008-08-08 2010-02-11 Howard Florey Institute Therapeutic methods and compositions
WO2013083574A1 (en) * 2011-12-05 2013-06-13 Key Neurosciences Sas Composition for treating parkinson's disease.

Also Published As

Publication number Publication date
EP3362081A4 (en) 2019-05-29
EP3362081B1 (en) 2021-12-08
WO2017066444A1 (en) 2017-04-20
EP3362081A1 (en) 2018-08-22
US10555989B2 (en) 2020-02-11
US20180280472A1 (en) 2018-10-04
JP2018534287A (ja) 2018-11-22

Similar Documents

Publication Publication Date Title
AU2021261907B2 (en) Use of myostatin inhibitors and combination therapies
US11738070B2 (en) Methods and compositions for improved cognition
JP6608309B2 (ja) Ｃｍｔ及び関連疾患の処置のための新規な治療的アプローチ
US9125862B2 (en) Methods for the treatment of Prader-Willi-like syndrome or non-organic failure to thrive (NOFITT) feeding disorder using an agonist of the oxytocin receptor
CN101288768A (zh) 用于治疗渐进神经退化症的医药组合物
AU2023233094B2 (en) Anti-inflammatory agents
JP6987749B2 (ja) Ｓｋチャネル阻害剤による学習障害および他の神経障害の治療
JP6928450B2 (ja) エンドセリンｂ受容体アゴニストを用いた、神経精神疾患を治療するための組成物及び方法
ES2617309T3 (es) Métodos y ensayos de tratamiento de sujetos con eliminación, mutación o expresión reducida de SHANK3
Ding et al. Dedicator of cytokinesis 2 (DOCK2) silencing protects against cerebral ischemia/reperfusion by modulating microglia polarization via the activation of the STAT6 signaling pathway
JP2017533967A (ja) システアミン組成物を用いるハンチントン病の処置方法
ES2377381B1 (es) Uso de una combinación de n-acetil-cisteína y ácido lipoico para la preparación de un medicamento útil para el tratamiento de una enfermedad con daño axonal y lesiones oxidativas concomitantes.
WO2021127003A1 (en) Treating heart disease in muscular dystrophy patients
Loan et al. Treatment options in motor neuron disease: Amyotrophic lateral sclerosis and spinal muscular atrophy
CN111588854A (zh) Trf2或其上调剂在制备治疗肌肉疾病的药物中的应用
Watson Obesity and the Hippocampus: How Diet-Induced Insulin Resistance Contributes to Memory Impairment
JP2017507941A (ja) 機械的な神経損傷を処置するための新規組成物
WO2021050689A1 (en) COMPOSITIONS, METHODS AND USES FOR TARGETING C-TERMINAL BINDING PROTEIN (CtBP) IN TRAUMATIC BRAIN INJURY
Harvey et al. FUNCTIONAL REGENERATION OF SENSORY AXONS INTO THE SPINAL CORD AFTER BLOCKADE OF MYELIN-ASSOCIATED INHI-BITION IN A DORSAL ROOT CRUSH MODEL OF SPINAL CORD IN-JURY
宮本和幸 Therapeutic time-window for edaravone treatment of traumatic brain injury in mice
Ahmed et al. Basic Research and Disease Models
Miyamoto et al. Research Article Therapeutic Time Window for Edaravone Treatment of Traumatic Brain Injury in Mice

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191011

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191105

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200825

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200915

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201125

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210215

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210629

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211001

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20211001

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20211011

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20211012

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211102

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211201

R150 Certificate of patent or registration of utility model

Ref document number: 6987749

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250